What is Pinealon?
Pinealon is a tripeptide investigated in experimental stress-response biology. The selected publication concerns cells under oxidative stress, rather than a clinical memory or dementia trial.
Biological role or research focus
Oxidative-stress responses in cells.
The study does not establish improved human memory, dementia prevention, or a clinically useful neuroprotective treatment.
Role reference: Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. · 2011 ↗
Names you may encounter
Glu-Asp-Arg · EDR peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Glu-Asp-Arg tripeptide
- Research focus
- Oxidative-stress responses in cells
- Featured evidence
- Cell study
- Source check
- October 4, 2026
Quick answers
- Is Pinealon FDA approved?
- No. No FDA-approved drug contains Pinealon. Source ↗
- Is Pinealon safe?
- Not an approved drug. Evidence is mostly cell and animal work plus one small Russian human report, so human safety is essentially unstudied. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Pinealon banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Pinealon under oxidative stress (2011) | Cell study | Cell preparations exposed to experimental oxidative stress. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Cell study · 2011
Pinealon under oxidative stress
What did this publication test, and what did it find?
- Population / model
- Cell preparations exposed to experimental oxidative stress.
- Study design
- Laboratory comparisons of cellular stress, viability, ERK signaling, and cell-cycle measures with Pinealon exposure.
- Main finding
- The report described lower reactive oxygen species and necrotic cell death, alongside changes in signaling and cell-cycle responses.
- Limits & context
- The study does not establish improved human memory, dementia prevention, or a clinically useful neuroprotective treatment.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Pinealon as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. ↗
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1 · Journal Article, Review
Read available full text ↗
[Investigation of antihypoxic properties of short peptides]. ↗
Advances in gerontology = Uspekhi gerontologii · 2008 · Journal Article
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. ↗
International journal of clinical and experimental medicine · 2012 · Journal Article
Read available full text ↗
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. ↗
Advances in gerontology = Uspekhi gerontologii · 2015 · English Abstract, Journal Article
Risks & interactions
Not an approved drug. Evidence is mostly cell and animal work plus one small Russian human report, so human safety is essentially unstudied.
One small Russian report (32 adults) described effects on aging markers but also noted pro-oxidant activity and lower blood stem-cell (CD34+) counts, which its authors read as suppressed blood-cell formation. It was not a controlled safety study.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Synthetic peptides (vesugen, pinealon) in patients with polymorbidity (2015) ↗ · Pinealon increases cell viability under oxidative stress (2011) ↗
Safety & what remains unknown
Cell viability under one experimental stress condition cannot establish systemic safety or long-term effects.
Evidence boundaries
The study does not establish improved human memory, dementia prevention, or a clinically useful neuroprotective treatment.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The research context includes cerebellar granule cells, neutrophils, and PC12 cells. Findings from these models should remain labeled as laboratory observations.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The investigators measured reactive oxygen species, cell death, and signaling responses. Changing a cell-stress marker is different from demonstrating better cognition in a person.
Questions worth asking
- Is this a human cognitive-enhancement trial?
- What material, population, and route were actually studied?
- The study does not establish improved human memory, dementia prevention, or a clinically useful neuroprotective treatment.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is this a human cognitive-enhancement trial?
No. It is a laboratory study of cell responses under oxidative stress.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
